Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.

Autor: Dey J; Presage Biosciences, Inc, Seattle, WA, USA., Deckwerth TL; Presage Biosciences, Inc, Seattle, WA, USA., Kerwin WS; Presage Biosciences, Inc, Seattle, WA, USA., Casalini JR; Presage Biosciences, Inc, Seattle, WA, USA., Merrell AJ; Presage Biosciences, Inc, Seattle, WA, USA., Grenley MO; Presage Biosciences, Inc, Seattle, WA, USA., Burns C; Presage Biosciences, Inc, Seattle, WA, USA., Ditzler SH; Presage Biosciences, Inc, Seattle, WA, USA., Dixon CP; Presage Biosciences, Inc, Seattle, WA, USA., Beirne E; Presage Biosciences, Inc, Seattle, WA, USA., Gillespie KC; Presage Biosciences, Inc, Seattle, WA, USA., Kleinman EF; Edward F. Kleinman LLC, Pawcatuck, CT, USA., Klinghoffer RA; Presage Biosciences, Inc, Seattle, WA, USA. rich.klinghoffer@presagebio.com.

Publikováno v: Scientific reports [Sci Rep] 2017 Dec 21; Vol. 7 (1), pp. 18007. Date of Electronic Publication: 2017 Dec 21.

Multidrug Analyses in Patients Distinguish Efficacious Cancer Agents Based on Both Tumor Cell Killing and Immunomodulation.

Autor: Frazier JP; Presage Biosciences, Inc., Seattle, Washington., Bertout JA; Presage Biosciences, Inc., Seattle, Washington., Kerwin WS; Presage Biosciences, Inc., Seattle, Washington., Moreno-Gonzalez A; Presage Biosciences, Inc., Seattle, Washington., Casalini JR; Presage Biosciences, Inc., Seattle, Washington., Grenley MO; Presage Biosciences, Inc., Seattle, Washington., Beirne E; Presage Biosciences, Inc., Seattle, Washington., Watts KL; Presage Biosciences, Inc., Seattle, Washington., Keener A; Presage Biosciences, Inc., Seattle, Washington., Thirstrup DJ; Presage Biosciences, Inc., Seattle, Washington., Tretyak I; Presage Biosciences, Inc., Seattle, Washington., Ditzler SH; Presage Biosciences, Inc., Seattle, Washington., Tripp CD; Veterinary Cancer Specialty Care, Lynnwood, Washington., Choy K; Oncology Department, Seattle Veterinary Specialists, Kirkland, Washington., Gillings S; Oncology Department, Summit Veterinary Referral Center, Tacoma, Washington., Breit MN; Oncology Department, BluePearl Veterinary Partners, Renton, Washington., Meleo KA; Oncology Department, BluePearl Veterinary Partners, Seattle, Washington., Rizzo V; Oncology Department, Summit Veterinary Referral Center, Tacoma, Washington., Herrera CL; Oncology Department, BluePearl Veterinary Partners, Seattle, Washington., Perry JA; Oncology Department, Seattle Veterinary Specialists, Seattle, Washington., Amaravadi RK; Abramson Cancer Center and Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Olson JM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.; Seattle Children's Hospital and Regional Medical Center, Seattle, Washington., Klinghoffer RA; Presage Biosciences, Inc., Seattle, Washington. rich.klinghoffer@presagebio.com.

Publikováno v: Cancer research [Cancer Res] 2017 Jun 01; Vol. 77 (11), pp. 2869-2880. Date of Electronic Publication: 2017 Mar 31.

A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.

Autor: Klinghoffer RA; Presage Biosciences, Seattle, WA 98109, USA., Bahrami SB; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Hatton BA; Presage Biosciences, Seattle, WA 98109, USA., Frazier JP; Presage Biosciences, Seattle, WA 98109, USA., Moreno-Gonzalez A; Presage Biosciences, Seattle, WA 98109, USA., Strand AD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Kerwin WS; Presage Biosciences, Seattle, WA 98109, USA., Casalini JR; Presage Biosciences, Seattle, WA 98109, USA., Thirstrup DJ; Presage Biosciences, Seattle, WA 98109, USA., You S; Presage Biosciences, Seattle, WA 98109, USA., Morris SM; Presage Biosciences, Seattle, WA 98109, USA., Watts KL; Presage Biosciences, Seattle, WA 98109, USA., Veiseh M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Grenley MO; Presage Biosciences, Seattle, WA 98109, USA., Tretyak I; Presage Biosciences, Seattle, WA 98109, USA., Dey J; Presage Biosciences, Seattle, WA 98109, USA., Carleton M; Presage Biosciences, Seattle, WA 98109, USA., Beirne E; Presage Biosciences, Seattle, WA 98109, USA., Pedro KD; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Ditzler SH; Presage Biosciences, Seattle, WA 98109, USA., Girard EJ; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Deckwerth TL; Presage Biosciences, Seattle, WA 98109, USA., Bertout JA; Presage Biosciences, Seattle, WA 98109, USA., Meleo KA; Oncology Department, BluePearl Veterinary Partners, Seattle, WA 98125, USA., Filvaroff EH; Celgene Corporation, San Francisco, CA 94158, USA., Chopra R; Celgene Corporation, Summit, NJ 07901, USA., Press OW; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA., Olson JM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.; Department of Pediatrics, University of Washington, Seattle, WA 98195, USA.; Seattle Children's Hospital, Seattle, WA 98105, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2015 Apr 22; Vol. 7 (284), pp. 284ra58.